Panelists discuss how evolving clinical evidence, real-world outcomes, and patient-reported data inform the selection, sequencing, and implementation of third-line therapies for metastatic colorectal cancer, highlighting the importance of individualized care, cross-setting collaboration, and strategies to enhance community adoption and patient quality of life.
EP. 1: Overview of Available Third-Line Options in mCRC
Panelists discuss how available third-line therapies, such as FTD/TPI, regorafenib, and others, are chosen based on survival data, safety, and patient quality of life.
Watch
EP. 2: Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer.
Watch